Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform study of iscalimab, LYS006, MAS825, and remibrutinib in moderate to severe hidradenitis suppurativa
NL-OMON52621Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iscalimab, LYS006, MAS825 and remibrutinib in hidradenitis suppurativa (HS), sponsored by Novartis. Started Aug 2020; status: active, not recruiting.
02
Drugs
iscalimabLYS006MAS825remibrutinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON52621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52621.